Discover innovations by
+ Research

Therapeutics

Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Binding Partner to Tumor Suppressor
  • HAUSP (herpesvirus-associated ubiquitin-specific protease) as a novel p53-interacting deubiquitinase. HAUSP strongly stabilizes p53 by deubiquitinating p53, even in the presence of excess Mdm2. In addition, HAUSP binds directly to Mdm2 in such a way as to form a three-protein complex with p53 and, via this indirect interaction, p53 is also stabilized. The technology provides methods for screening HAUSP-p53 and HAUSP-Mdm2 interactions.
  • Read more
  • TherapeuticsMethods
  • New York, NY, United States
  • Stanford University
Back
or
Back
Back
or
Back
Back
or
Back
  • Treatment for Chronic Dry Eye Syndrome
  • Aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions: Meibomian secretions are composed of a heterogenous lipid mixture, which forms a protective lipid surface that maintains the integrity of the tear film. This invention provides an aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions.
  • Read more
  • Therapeutics
  • New York, NY, United States
  • Stanford University
Back
or
Back
Back
or
Back
Back
or
Back
  • siRNA Delivery to Inhibit Tumor Growth in the Central Nervous System
  • This invention provides compositions and methods that utilize a cell-permeable complex for facilitating the delivery of a double-stranded RNA into the central nervous system (CNS) to reduce the expression of a target protein, and in turn inhibit the growth of a tumor. Specifically, by convection-enhanced delivery to the CNS, a cell-permeable complex comprises a double stranded RNA that is effective in inhibiting the expression of the target protein, operably linked to a cell penetrating peptide.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Cancer Therapeutics Targeting Oncogenic-RAS- Expressing Tumor Cells
  • This technology describes methods for identifying an agent, which induces oxidative cell death in a tumor cell. The methods comprise determining the voltage dependent anion channel (VDAC) level in a tumor cell, and determining whether the tumor cell dies via oxidative cell death in the presence of a test agent. Furthermore, this technology provides a class of novel RAS-selective-lethal compounds capable of causing rapid and non-apoptotic cell death in oncogenic-RAS-expressing tumor cells.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Columbia University
Back
or
Back
  • Treatment of Inherited and Genetic Cardiomyopathies by ERK Inhibition
  • This technology discovered that genes related to the ERK and JNK pathways exhibited statistically different expression at the incipience of the development of cardiomyopathies. Treatment with ERK inhibitor alone or treatment with both JNK inhibitor and ERK inhibitor significantly improved cardiac function assessed by echocardiography in EDMD mice. Activation of ERK or ERK plus JNK can lead to heart disease in EDMD and other inherited cardiomyopathies.
  • Read more
  • TherapeuticsMethods
  • New York, NY, United States
  • Columbia University
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
  • Nitrosation-inducible Cytotoxins: A New Class of Therapeutics
  • Nitric oxide (•NO) is a free radical involved in numerousphysiological and pathological processes in mammals. NO is producedendogenously by a family of enzymes known as NO synthases (NOS). NO ischemically unreactive towards most bioorganic compounds, but it can rapidly andspontaneously auto-oxidize to yield the highly reactive species, N2O3, whichcovalently modifies (nitrosates) free thiol and amino groups. High levels of NOsynthesis and nitrosation are generally associated with immune response againstbacteria and viruses.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • New York University
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
  • Fibrin Binding Peptides
  • Discovery of physical sites on Fn that bind to fibrin. The physical bindinginteraction between Fn and fibrin is critical to fibrin clot formation, as annecessary step in the wound repair process. Proteins, such as t-PA, that engagein fibrin binding have similar molecular structures however, the Fn dimer showsan affinity of two logs higher than any other fibrin-binding protein.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • New York University
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
← Previous Next → 1 2 3 4
Showing 1-40 from 160

Send Us a Message